Lexicon Pharmaceuticals (LXRX) Capital Expenditures (2010 - 2024)

Lexicon Pharmaceuticals (LXRX) has 15 years of Capital Expenditures data on file, last reported at $474000.0 in Q4 2024.

• Capital Expenditures for Q4 2024 came in at $474000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $781000.0 (down 24.25% YoY), and the FY2024 annual result was $1.0 million, up 119.36% from the prior year.
• Capital Expenditures advanced to $474000.0 in Q4 2024 per LXRX's latest filing, from $307000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $1.2 million in Q4 2022 and troughed at $4000.0 in Q3 2022.
• A 5-year average of $275666.7 and a median of $139000.0 in 2023 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 5317.39% in 2022 and fell as far as 98.12% in 2022.
• A 5-year view of Capital Expenditures shows it stood at $54000.0 in 2020, then plunged by 57.41% to $23000.0 in 2021, then jumped by 5317.39% to $1.2 million in 2022, then plunged by 93.34% to $83000.0 in 2023, then jumped by 471.08% to $474000.0 in 2024.
• Business Quant data shows LXRX's Capital Expenditures at $474000.0 in Q4 2024, $307000.0 in Q3 2024, and $250000.0 in Q2 2024.